The price of Organon & Co (NYSE:OGN) shares last traded on Wall Street rose 0.97% to $14.58.
OGN stock price is now -9.76% away from the 50-day moving average and -23.38% away from the 200-day moving average. The market capitalization of the company currently stands at $3.79B.
With the price target enhanced from $18 to $20, JP Morgan Downgraded its rating from Neutral to Underweight for Organon & Co (NYSE: OGN). On November 03, 2023, Goldman Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $33 to quote $16, while ‘Barclays’ rates the stock as ‘Overweight’
In other news, Weaver Kirke, Gen. Counsel & Corp. Secy. bought 2,720 shares of the company’s stock on Feb 22 ’24. The stock was bought for $49,939 at an average price of $18.36. Upon completion of the transaction, the Gen. Counsel & Corp. Secy. now directly owns 15,181 shares in the company, valued at $0.22 million. A total of 0.22% of the company’s stock is owned by insiders.
During the past 12 months, Organon & Co has had a low of $13.14 and a high of $23.10. As of last week, the company has a debt-to-equity ratio of 17.75, a current ratio of 1.70, and a quick ratio of 1.21. According to the stock market information, the enterprise value for the company is $11740916736, which is based on a 2.89 price-to-earnings ratio, a 0.56 price-to-earnings-growth ratio, and a beta of 0.72. The fifty day moving average price for OGN is $16.1564 and a two-hundred day moving average price translates $19.02975 for the stock.
The latest earnings results from Organon & Co (NYSE: OGN) was released for 2024-09-30. The company reported revenue of $1.58 billion for the quarter, compared to $1.52 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 4.15 percent.
